Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Niadyne Inc.

This article was originally published in Start Up

Executive Summary

Niadyne Inc.'s scientific founders have devoted their academic careers to the biological causes of skin cell injury and methods for its repair. The company has developed nutrient-based compounds to combat the DNA damage that leads to deterioration in skin's appearance, as well as a topical system to deliver them. Niadyne's initial products will be marketed as cosmeceuticals, but it aims to pursue longer-term therapeutic interests in wound healing and heart disease.

You may also be interested in...



Skin Repair

A handful of start-ups hopes to fill the cracks in the fragmented market for skin repair. Their approaches vary widely; British start-up Renovo has a pharmaceutical approach to the prevention of scarring. Reconstructive Technologies believes that the best replacement for skin is skin itself; it has developed a bioreactor that accelerates the growth of autograft skin, with both {in vivo} and {in vitro} systems. Artecel Sciences will use adipose-derived stromal cells in cosmesis and hematopoietic support. Niadyne 's platform of unique formulations of niacin lend themselves to a variety of applications, in cosmeceuticals and in cardiovascular disease.

In Vivo's Deals Of The Month, February 2018

In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)

In Vivo's Deals Of The Month, January 2018

In Vivo's editors pick January's most significant deals, including an alliance of players new to health care and Celgene's big buys. (Free article.)

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC100339

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel